Corcept Therapeutics Incorporated

Stage 2 · Advancing · week 18

As of Oct 22, 2026, Corcept Therapeutics is in Stage 2, the uptrend phase, now in week 18 (since Jun 23, 2026). It closed at $107.50, 13.0% below its 52-week high and above its 200-day average, which is rising.

$107.50

-7.55% today

$11.6B · Large cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is CORT early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 56w

S2 14w

S4 14w

S2 17w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 10w → S3 9w → S2 3w → S3 1w → S4 10w → S1 9w → S2 56w → S3 1w → S2 2w → S3 8w → S2 14w → S3 1w → S4 14w → S1 10w → S2 17w current

Total tracked: 166 weeks across 15 stage runs.

CORT among Biotechnology102nd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…102	CORTCorcept Therapeutics Incorporated	Stage 2 · wk 18	83	−4.8%

vs 52W High

-13.0%

$32.15 lo$123.57 hi

13.0% below 52W high, pullback range

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 18

1w13w26w

Week 18, proven structure

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

46.6%

200 DMA: $73.30 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.71x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↗

Short-term trend rising gently

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-4.8%

+12.7%

+138.5%

YTD

+181.4%

+42.6%

Scan Membership

Breakout Watch

Latest: 2024-06-12

10 appearances in last 60 days. First seen: 2019-09-17.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 18 · Vol 0.71x

2026-10-21S2

Wk 17 · Vol 0.45x

2026-10-20S2

Wk 17 · Vol 0.47x

2026-10-19S2

Wk 17 · Vol 0.34x

2026-10-16S2

Wk 17 · Vol 0.73x

2026-10-15S2

Wk 17 · Vol 0.57x

2026-10-14S2

Wk 16 · Vol 0.59x

2026-10-13S2

Wk 16 · Vol 0.46x

2026-10-12S2

Wk 16 · Vol 0.40x

2026-10-09S2

Wk 16 · Vol 0.48x

2026-10-08S2

Wk 16 · Vol 0.37x

2026-10-07S2

Wk 15 · Vol 0.48x

Moving averages & range

50 DMA

$115.70

200 DMA

$73.30

52W High

$123.57

52W Low

$32.15

5D Low

$107.50

Resistance levels (recent highs)

20d High

$122.03

60d High

$123.57

120d High

$123.57

250d High

$123.57

Next resistance

+13.5%

to 20d High

P/E (TTM)

238.9

Forward 24.4

Earnings Growth (YoY)

+24.1%

Revenue +31.7%

ROE

+8.2%

Profit margin +6.6%

Dividend Yield

0.00%

P/B 16.4

Corcept Therapeutics: quick answers

What stage is Corcept Therapeutics in?

As of Oct 22, 2026, Corcept Therapeutics (CORT) is in Stage 2, the uptrend phase. It entered Stage 2 on Jun 23, 2026 and is in week 18. What the four stages mean

Is Corcept Therapeutics in an uptrend?

Yes. Corcept Therapeutics is in a Stage 2 uptrend. It trades 46.6% above its 200-day average, which is rising.

How far is Corcept Therapeutics from its 52-week high?

Corcept Therapeutics closed at $107.50 on Oct 22, 2026, 13.0% below its 52-week high of $123.57. Its 52-week low is $32.15.

How has Corcept Therapeutics performed over the past year?

As of Oct 22, 2026, Corcept Therapeutics is up 42.6% over the past year and up 181.4% so far in 2026.

Which sector and industry is Corcept Therapeutics in?

Corcept Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.